ENZO BIOCHEM, INC.: net income or loss

What this measure means

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Exact concept: us-gaap:NetIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-08-01 to 2024-07-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• ENZO BIOCHEM, INC.: total assets
• ENZO BIOCHEM, INC.: total liabilities
• ENZO BIOCHEM, INC.: stockholders equity
• ENZO BIOCHEM, INC.: cash and cash equivalents
• ENZO BIOCHEM, INC.: operating cash flow
• ENZO BIOCHEM, INC.: capital expenditure payments
• ENZO BIOCHEM, INC.: revenue
• ENZO BIOCHEM, INC.: financing cash flow
• ENZO BIOCHEM, INC.: investing cash flow
• ENZO BIOCHEM, INC.: retained earnings or deficit
• ENZO BIOCHEM, INC.: basic weighted-average shares
• ENZO BIOCHEM, INC.: diluted weighted-average shares
• ENZO BIOCHEM, INC.: basic earnings per share
• ENZO BIOCHEM, INC.: diluted earnings per share
• ENZO BIOCHEM, INC.: income tax expense or benefit
• ENZO BIOCHEM, INC.: net property, plant and equipment
• ENZO BIOCHEM, INC.: share-based compensation expense
• ENZO BIOCHEM, INC.: operating income or loss
• ENZO BIOCHEM, INC.: current assets
• ENZO BIOCHEM, INC.: interest expense
• ENZO BIOCHEM, INC.: current liabilities
• ENZO BIOCHEM, INC.: goodwill carrying amount
• ENZO BIOCHEM, INC.: net finite-lived intangible assets
• ENZO BIOCHEM, INC.: net current accounts receivable
• ENZO BIOCHEM, INC.: net inventory
• ENZO BIOCHEM, INC.: cost of revenue
• ENZO BIOCHEM, INC.: selling, general and administrative expense
• ENZO BIOCHEM, INC.: research and development expense
• ENZO BIOCHEM, INC.: common shares outstanding
• ENZO BIOCHEM, INC.: cash including restricted cash
• ENZO BIOCHEM, INC.: additional paid-in capital
• ENZO BIOCHEM, INC.: accumulated other comprehensive income or loss
• ENZO BIOCHEM, INC.: operating lease right-of-use asset
• ENZO BIOCHEM, INC.: operating lease liability
• ENZO BIOCHEM, INC.: long-term debt
• ENZO BIOCHEM, INC.: gross property, plant and equipment
• ENZO BIOCHEM, INC.: accumulated depreciation on property, plant and equipment
• ENZO BIOCHEM, INC.: net intangible assets excluding goodwill
• ENZO BIOCHEM, INC.: other noncurrent assets
• ENZO BIOCHEM, INC.: other noncurrent liabilities
• ENZO BIOCHEM, INC.: accrued current liabilities
• ENZO BIOCHEM, INC.: prepaid expenses and other current assets
• ENZO BIOCHEM, INC.: net deferred tax assets
• ENZO BIOCHEM, INC.: pre-tax income or loss from continuing operations
• ENZO BIOCHEM, INC.: profit or loss including noncontrolling interests
• ENZO BIOCHEM, INC.: comprehensive income or loss
• ENZO BIOCHEM, INC.: depreciation expense
• ENZO BIOCHEM, INC.: depreciation, depletion and amortization
• ENZO BIOCHEM, INC.: amortization of intangible assets
• ENZO BIOCHEM, INC.: other nonoperating income or expense
• ENZO BIOCHEM, INC.: deferred income tax expense or benefit
• ENZO BIOCHEM, INC.: interest paid, net
• ENZO BIOCHEM, INC.: income taxes paid, net
• ENZO BIOCHEM, INC.: proceeds from issuing common stock
• ENZO BIOCHEM, INC.: change in accounts receivable
• ENZO BIOCHEM, INC.: change in inventories

Inspect the source

Entity

ENZO BIOCHEM, INC. / CIK 0000316253

Captured

2026-09-21T17:16:29.907Z

SEC response SHA-256

67c7d8ab8d53eeffbfcdac94db6885f7023568fea5a2f682b0082524251fa5d5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000316253.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))